Create Free Account

By creating account you will get access to hot stocks & personalised emails

Australian Clinical Labs Ltd

Healthcare AU ACL

3.58AUD
-0.01(0.28%)

Last update at 2024-11-13T05:10:00Z

Day Range

3.523.62
LowHigh

52 Week Range

2.083.85
LowHigh

Fundamentals

  • Previous Close 3.59
  • Market Cap738.06M
  • Volume741271
  • P/E Ratio30.50
  • Dividend Yield4.90%
  • EBITDA76.31M
  • Revenue TTM696.37M
  • Revenue Per Share TTM3.50
  • Gross Profit TTM 250.42M
  • Diluted EPS TTM0.12

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 48.31M 254.90M 86.65M 30.83M -9.70400M
Minority interest -0.14100M -0.15800M 0.02M 0.02M 0.02M
Net income 35.90M 178.24M 60.37M 41.26M -10.52400M
Selling general administrative 297.39M 314.00M 249.69M 266.73M 322.53M
Selling and marketing expenses - - - - -
Gross profit 566.02M 781.71M 521.73M 403.53M 369.04M
Reconciled depreciation 122.75M 106.10M 88.05M - -
Ebit 64.02M 256.24M 97.59M 18.47M -5.01300M
Ebitda 174.60M 362.33M 185.64M - -
Depreciation and amortization - 106.10M 88.05M - -
Non operating income net other - - - - -
Operating income 51.97M 256.24M 97.59M 47.42M -5.80200M
Other operating expenses - 721.62M 536.12M 44.65M 47.25M
Interest expense 3.54M 1.34M 10.94M 0.10M 0.07M
Tax provision 12.27M 76.50M 26.26M -10.42500M 0.82M
Interest income 0.18M 0.04M 21.89M 16.59M 3.90M
Net interest income -13.68300M -11.70400M -21.89400M - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 76.50M 26.26M -10.42500M 0.82M
Total revenue 692.10M 989.30M 641.31M 490.57M 448.45M
Total operating expenses - 514.03M 416.54M - -
Cost of revenue 126.08M 207.59M 119.58M 87.04M 79.41M
Total other income expense net 10.03M -1.07300M 3.36M - -
Discontinued operations - - - - -
Net income from continuing ops 36.04M 178.40M 60.39M - -
Net income applicable to common shares - 178.24M 60.37M 41.26M -10.52400M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 593.06M 578.91M 628.04M 474.70M 366.05M
Intangible assets - 6.49M 6.72M 6.92M -
Earning assets - - - - -
Other current assets 8.50M 0.63M 1.13M 1.05M 0.01M
Total liab 415.30M 406.24M 395.49M 392.79M 297.06M
Total stockholder equity 177.53M 172.42M 232.44M 81.90M 68.99M
Deferred long term liab - - - - -
Other current liab 73.57M 25.09M 103.93M 78.94M 22.58M
Common stock 791.76M - 793.03M 797.98M 146.50M
Capital stock - 792.14M 793.03M 47.10M -
Retained earnings 159.05M 22.45M 216.22M 62.19M -79.03300M
Other liab - - 2.71M 2.56M 3.83M
Good will 158.68M 158.68M 158.68M 105.98M 35.75M
Other assets 0.00000M - 9.57M 15.62M 23.16M
Cash 26.14M 19.95M 26.37M 35.23M 34.85M
Cash and equivalents - - 26.37M 35.23M 34.85M
Total current liabilities 207.70M 187.93M 225.16M 166.18M 135.47M
Current deferred revenue 3.24M - 92.11M 78.27M -
Net debt 282.76M 45.74M 236.00M 259.03M -
Short term debt 104.71M - 94.77M 70.21M 0.00000M
Short long term debt - - - -0.30000M -
Short long term debt total 308.90M - 262.38M 294.26M 157.76M
Other stockholder equity - -642.17600M -644.01900M -645.48300M 1.52M
Property plant equipment - - 310.20M 238.34M 194.05M
Total current assets 133.60M 115.96M 142.87M 117.23M 112.10M
Long term investments - - - 1.00M -
Net tangible assets - - 67.04M -31.00800M 33.24M
Short term investments 0.71M - 1.13M 1.05M 0.43M
Net receivables 81.43M 51.35M 91.11M 62.98M 63.31M
Long term debt - 65.70M 0.00000M 99.51M 60.07M
Inventory 16.83M 15.09M 20.09M 13.36M 10.50M
Accounts payable 26.19M 17.97M 26.47M 17.02M 12.89M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -773.28800M - -776.80700M -778.27100M -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.07M 1.11M 0.15M - -
Deferred long term asset charges - - - - -
Non current assets total 459.46M 462.95M 485.17M 357.48M -
Capital lease obligations - 250.62M 262.38M 160.10M -
Long term debt total - - 167.61M 224.06M 157.76M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -12.18200M -72.04300M 1.07M 1.07M 0.15M
Change to liabilities 0.00000M 16.49M 5.17M 5.75M -2.91700M
Total cashflows from investing activities - -72.04300M -6.07600M -9.95800M -12.84700M
Net borrowings - -191.68700M -35.62400M -60.91600M -4.88800M
Total cash from financing activities -137.87600M -220.91000M -147.37000M -60.91600M 8.99M
Change to operating activities - 5.01M 7.34M 0.34M 2.03M
Net income 35.90M 178.24M 60.37M 41.26M -10.52400M
Change in cash -6.37700M -8.86100M 0.38M 30.72M -2.73600M
Begin period cash flow 26.37M 35.23M 34.85M - -
End period cash flow 19.95M 26.37M 35.23M 34.85M -
Total cash from operating activities - 284.09M 153.86M 101.74M 1.11M
Issuance of capital stock - - 146.25M - -
Depreciation - 106.10M 88.05M 77.90M 11.51M
Other cashflows from investing activities - -50.79100M 3.43M -0.57700M 0.99M
Dividends paid 96.88M 24.28M 42.00M 42.00M 42.00M
Change to inventory - -3.89800M -2.26100M -0.82800M -0.42300M
Change to account receivables - -28.11900M 2.75M -16.80300M -3.76700M
Sale purchase of stock -0.89100M -4.94400M 321.60M 0.00000M 14.41M
Other cashflows from financing activities - -91.68700M 17.97M -216.00000M -216.00000M
Change to netincome -8.73400M 10.27M -7.56500M -5.88300M 5.21M
Capital expenditures 6.93M 21.25M 9.51M 9.38M 14.36M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital - 0.04M 0.07M 0.04M 0.04M
Stock based compensation - - - - -
Other non cash items - - - - -
Free cash flow 136.75M -21.25200M -9.50600M - -

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ACL
Australian Clinical Labs Ltd		 -0.01 0.28% 3.58 30.50 12.24 1.06 4.17 1.48 6.03
SHL
Sonic Healthcare Ltd		 -0.23 0.86% 26.46 25.36 22.32 1.45 1.65 1.90 10.21
HLS
Healius Ltd		 -0.015 0.95% 1.56 - 163.93 0.65 1.09 1.53 10.14
IDX
Integral Diagnostics Ltd		 -0.1 3.19% 3.03 - 20.96 1.52 2.33 2.17 151.08
MVF
Monash IVF Group Ltd		 -0.015 1.29% 1.15 - 14.99 1.80 1.91 2.30 54.34

Reports Covered

Stock Research & News

View All

Profile

Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offers its service to private and public hospitals. The company was incorporated in 2020 and is headquartered in Clayton, Australia.

Australian Clinical Labs Ltd

1868-1892 Dandenong Road, Clayton, VIC, Australia, 3168

Key Executives

Name Title Year Born
Ms. Melinda McGrath CEO & Exec. Director NA
Mr. James Davison Chief Financial Officer NA
Mr. Anthony Friedli Chief Operating Officer NA
Mr. Sean Jackson Chief Information Officer NA
Mr. Joe Geran National Marketing Director NA
Associate Prof. Tony Landgren National Medical Director & Chief Pathologist NA
Mr. Chris Brownlow Chief Exec. Officer of New South Wales & Australian Capital Territory NA
Ms. Shae Seymour Chief Exec. Officer of Western Australia NA
Mr. Eric Swayn Chief Exec. Officer of South Australia & Northern Territory NA
Ms. Eleanor Padman B.A., FCIS Company Sec. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.